Last reviewed · How we verify
NCT03104569
Effect of 37℃ Non-ionic Contrast Agent During ERCP Procedure in Hilar Cholangiocarcinoma
NA trial testing Injection of 37℃ contrast agent in Cholangitis in 100 participants. Not yet recruiting.
1 December 2028
Quick facts
| Lead sponsor | Hepatopancreatobiliary Surgery Institute of Gansu Province |
|---|---|
| Phase | NA |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | triple |
| Primary purpose | treatment |
| Enrollment | 100 |
| Start date | 1 April 2026 |
| Primary completion | 1 December 2028 |
| Estimated completion | 1 December 2028 |
| Sites | 3 locations across China |
Drugs / interventions tested
- Injection of 37℃ contrast agent
Conditions studied
- Cholangitis — all drugs for Cholangitis →
Sponsor
Hepatopancreatobiliary Surgery Institute of Gansu Province
Who can join
Adults 18 to 90, any sex, with Cholangitis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to determine the effect of normal temperature and 37℃ non-ionic contrast agent acting on ERCP-related cholangeitis after endoscopic retrograde cholangiopancreatography (ERCP) in the treatment of hilar cholangiocarcinoma.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03104569
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Cholangitis
Currently open trials in the same condition.
- NCT05750966 — Short-course Antibiotics vs Standard Course Antibiotics in Patients With Cholangitis · NA · active not recruiting
- NCT05925309 — Preventive Effect of Prophylactic Oral Antibiotics Against Cholangitis After Kasai Portoenterostomy · NA · recruiting
- NCT05061680 — Quick Large Balloon Dilatation for Removal of Large Bile Duct Stones (SHODBADI) · NA · recruiting
Other Hepatopancreatobiliary Surgery Institute of Gansu Province trials
Trials by the same sponsor.
- NCT07321431 — The Optimal Measurement Time for the New Gallbladder Function Assessment Method · NA · recruiting
- NCT07091526 — Whether Control of Serum Uric Acid (SUA) Improves Survival After Pancreatic Cancer · recruiting
- NCT07039864 — A Novel Strategy for Evaluating Gallbladder Contraction Function by Ultrasound · NA · completed
- NCT06697405 — Impact of Cardiopulmonary Bypass Time on Gastrointestinal Complications · completed
- NCT06699030 — A Strategy for Gallstone Expulsion Through Dietary Therapy · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03104569 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hepatopancreatobiliary Surgery Institute of Gansu Province
- Last refreshed: 26 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03104569.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing